Floatz logo

Iodixanol

Bone Metastases

M.D. Anderson Cancer CenterSmall moleculeDormant
D
30/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
15/ 100
Competitive Position
89/ 100

Competitive context

24 Active assets in the Bone Metastases cohort.

Asset / SponsorPhaseRating
Denosumab
Kelly Fitzgerald, MD
Phase 4BBB
Zoledronate
Kelly Fitzgerald, MD
Phase 4BBB
RADIUM RA-223
University of California, San Francisco
Phase 3BB
Zometa
Sun Yat-sen University
Phase 4BB
TECHNETIUM TC-99M CATION, UNSPECIFIED
University of California, San Francisco
Phase 3BB

View all 50 →

Same molecule, other indications

Iodixanol is also rated in:

carotid stenosisDormant
B
Indicative ·
63 / 100
View asset →
atherosclerosisDormant
B
Indicative ·
62 / 100
View asset →
Colon CancerDormant
B
Indicative ·
59 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →